预约演示
更新于：2025-04-19
Bromfenac Sodium
溴芬酸钠
更新于：2025-04-19
概要
基本信息
非在研机构 |
最高研发阶段批准上市 |
首次获批日期 美国 (1997-07-15), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C30H30Br2N2Na2O9 |
InChIKeyUCZFEKWQIBDZNH-UHFFFAOYSA-N |
CAS号120638-55-3 |
关联
67
项与 溴芬酸钠 相关的临床试验NCT05626478
Assessing eFficacy and Safety of DEXTENZA 0.4 mg inseRt in Conjunction With Topical Drop Regimen Treating Pain and inflamMation Following Cataract Surgery Compared to SOC Topical Drop Regimen
NCT06785090
Effects of Topical Bromfenac Solution on Macular Thickness in Cataract Patients Undergoing Phacoemulsification Surgery
NCT05107921
Efficacy of Bromfenac Sodium Hydrate Eye Drops in Children With Familial Exudative Vitreoretinopathy After Diode Laser Photocoagulation
100 项与 溴芬酸钠 相关的临床结果
登录后查看更多信息
100 项与 溴芬酸钠 相关的转化医学
登录后查看更多信息
100 项与 溴芬酸钠 相关的专利（医药）
登录后查看更多信息
399
项与 溴芬酸钠 相关的文献（医药）2025-03-01VETERINARY OPHTHALMOLOGY
Low‐dose intravitreal injection of 4 mg preservative‐free gentamicin and superficial lamellar keratectomy combined with modified Gundersen grafts to control chronic heterochromic iridocyclitis and secondary keratitis in horses
Article
作者: Charnock, Lauren N. ; McMullen, Richard J.
Abstract:
Objective:
To describe a combined treatment approach for heterochromic iridocyclitis and secondary keratitis (HIK) in horses.
Animal Studied:
A total of 15 horses (16 eyes).
Procedures:
Sixteen eyes from 15 horses (mean age 14.1 years, range 6–26 years) received low‐dose (4 mg) intravitreal preservative‐free gentamicin injection (IVGI) and modified Gundersen grafts with standing sedation and local anesthesia following a clinical diagnosis of HIK. Additional therapies of suprachoroidal triamcinolone (8 mg) injection, episcleral bromfenac implants, and suprachoroidal cyclosporine implants were performed in individual cases. Leptospira titers were also reported when available.
Results:
The most frequent ophthalmic findings were pigmented keratic precipitates (n = 15/16 eyes, 94%), corneal edema (n = 14/16 eyes, 88%), and pigmented cells suspended in the anterior chamber (n = 7/16 eyes, 44%). Postoperative treatment generally consisted of topical and systemic NSAIDs, topical antibiotics, and a topical mydriatic agent. Complications included persistent corneal edema (7/16, 44%), corneal ulceration (6/16, 38%), graft failure requiring revision (2/16, 13%), stromal abscess (1/16, 6%), surgery site infection (1/16, 6%), and suspected retinal degeneration following IVGI (1/16, 6%). One case was enucleated 6 months after treatment (1/16, 6%). Of the 12 eyes with at least 3 months of post‐treatment follow‐up, 10 were comfortable and visual with static or improved symptoms of HIK.
Conclusions:
This multimodal treatment approach aims to address both the anterior uveitis and endothelial decompensation frequently seen in horses with HIK. The surgery can be performed under standing sedation. Continued evaluation and long‐term follow‐up is necessary in all horses with HIK.
2024-12-01EYE
Topical NSAIDs impact on macular oedema and visual outcome after phacoemulsification: systematic review of RCTs with network meta-analysis
Review
作者: Gavris, Iulia ; Almasri, Malaz ; Nicoara, Simona Delia ; Leucuta, Daniel-Corneliu ; Gavris, Monica M ; Ismaiel, Abdulrahman
Abstract:
The aim of this Network Meta-analysis was to compare the efficacy of the different topical Nonsteroidal anti-inflammatory drugs (NSAIDs) when added or not to topical steroids in preventing the thickening of the macula and their impact on visual acuity and intraocular pressure after phacoemulsification. Five electronic databases were searched, including PubMed, Embase, Scopus, Cochrane Library, and ClinicalTrials.gov. Our primary outcome was one-month post-surgery visual outcome. We also considered change in Foveal thickness (FT) and Intraocular pressure (IOP) at one-month post-surgery. We summarized our analyses by calculating the mean differences (MD) with associated 95% confidence intervals (CI) using restricted maximum likelihood in random effects models for continuous outcomes. The methodological quality of the studies was assessed with Cochrane Collaboration’s tool. The network meta-analysis was conducted using frequentist approach considering Nepafenac 0.1% as a reference medication. Eleven Randomized controlled trials (RCTs) including 2175 subjects were selected for quantitative analysis. At one-month post-surgery, Bromfenac had statistically significant better visual acuity compared to Nepafenac 0.1% (p < 0.001), regarding FT, Nepafenac 0.3% had the least increase in FT compared to Nepafenac 0.1% (p = 0.09), regarding IOP, Diclofenac had the lowest IOP. No significant results regarding FT and IOP. Interestingly Ketorolac had the worst results regarding BCVA and IOP, and came last but one for FT. Overall, our network meta-analysis demonstrated that Bromfenac was associated with a significant improvement in visual acuity compared to Nepafenac 0.1% at one-month following cataract surgery, while Nepafenac 0.3% was associated with the least increase in foveal thickness.
2024-10-01JOURNAL OF CATARACT AND REFRACTIVE SURGERY
Topical nonsteroidal anti-inflammatory drugs for management of pain after PRK: systematic review and network meta-analysis
Review
作者: Ben Ephraim Noyman, Dror ; Mimouni, Michael ; Gonzalez-Lugo, Javier H ; Sommer, Adir C ; Naaman, Efrat
Topic::
Topical nonsteroidal anti-inflammatory drugs (NSAIDs) for management of pain in patients after photorefractive keratectomy (PRK).
Clinical Relevance::
Pain after PRK is a major concern for both patients and surgeons. Although evidence supports the use of NSAIDs postoperatively, no consensus exists regarding the preferred regimen. The study aimed to compare the efficacy and safety of different topical NSAIDs.
Methods::
This study was prospectively registered with PROSPERO (ID: CRD42023417651). A systematic search of electronic databases was performed, for randomized controlled trials reporting topical NSAIDs' outcomes of corneal re-epithelization, rescue analgesics intake, and pain in days 0 to 3 after PRK (postoperative days [PODs] 0 to 3). Studies were graded for risk of bias. Data were extracted, and standardized mean differences (SMDs) were evaluated in a network meta-analysis in accordance with the Cochrane's guidelines, to which a frequentist approach model was fitted. Transitivity was assessed using the net split method. Treatment effectiveness was ranked using forest plots based on comparison with placebo. P-scores (P) and league tables were used to examine combined direct and indirect comparisons.
Results::
Of 1540 studies identified, 27 were included. These encompassed 2286 patients across 11 countries, evaluating 7 distinct topical NSAIDs. At POD0, ketorolac (P 0.764), flurbiprofen (P 0.763), and bromfenac (P 0.717) were the most efficient drugs overall and displayed significantly lower pain scores than placebo. Other than that, flurbiprofen held the highest rank for reported pain throughout, significantly outperforming placebo on POD1 (P 0.874, SMD −1.19, 95% CI −1.86 to −0.52), POD2 (P 0.882, SMD −1.05, 95% CI −1.82 to −0.27), and POD3 (P 0.939, SMD −1.14, 95% CI −2.1 to −0.18). Other NSAIDs were significantly better than placebo only on POD1 and POD0. Rescue analgesic intake analysis favored indomethacin (P 0.834, SMD −0.8, 95% CI −1.33 to −0.27), ketorolac, and diclofenac. Compared with placebo, re-epithelization was slowed to different significances with all NSAIDs but flurbiprofen (P 0.991, SMD −0.7, 95% CI −1.38 to −0.03).
Conclusions::
Flurbiprofen was favorable in pain scores on typically painful postoperative days and re-epithelization times. However, analgesics intake, a more objective outcome, suggested superiority of other NSAIDs. Inconsistencies may be explained by the small sample size. For clinical interpretation, NSAID effect sizes should be taken into consideration.
100 项与 溴芬酸钠 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 眼部炎症 | 中国 | 2009-01-01 | |
| 睑缘炎 | 日本 | 2008-03-14 | |
| 结膜炎 | 日本 | 2008-03-14 | |
| 巩膜炎 | 日本 | 2008-03-14 | |
| 眼睛疼痛 | 美国 | 2006-01-27 | |
| 术后炎症 | 美国 | 2006-01-27 | |
| 白内障 | 美国 | 2005-03-24 | |
| 疼痛 | 美国 | 1997-07-15 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 干眼综合征 | 临床3期 | 美国 | 2010-09-01 | |
| 炎症 | 临床3期 | 美国 | 2009-02-01 | |
| 变应性结膜炎 | 临床3期 | 美国 | 2006-11-01 | |
| 眼科外科手术 | 临床3期 | 美国 | 2003-05-01 | |
| 术后并发症 | 临床3期 | 美国 | 2003-05-01 | |
| 糖尿病性黄斑水肿 | 临床1期 | 美国 | 2007-06-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 35 | (LessDrops) | 衊繭獵獵襯壓鬱壓鑰糧(廠鏇鬱範鏇艱繭觸製齋) = 艱糧淵蓋簾壓憲壓壓鹹 顧築鏇觸遞醖獵鏇鹹憲 (築夢繭製繭鹽壓顧繭醖, 8.46) 更多 | - | 2022-06-10 | ||
衊繭獵獵襯壓鬱壓鑰糧(廠鏇鬱範鏇艱繭觸製齋) = 衊選襯夢積鏇衊鑰築鏇 顧築鏇觸遞醖獵鏇鹹憲 (築夢繭製繭鹽壓顧繭醖, 4.13) 更多 | |||||||
临床4期 | 46 | Artificial tears+Bromfenac (Group A: Bromfenac Then Artificial Tears) | 夢膚觸蓋選餘範鹽淵鹽(壓鹽製窪醖繭餘鏇襯遞) = 繭鹹餘醖觸蓋簾鹽艱網 遞顧簾顧簾簾壓簾顧願 (膚範鏇窪鹹憲襯遞繭願, 鏇構鑰壓鹹獵製醖膚範 ~ 願醖觸積範鬱積艱範衊) 更多 | - | 2020-10-19 | ||
Artificial tears+Bromfenac (Group B: Artificial Tears Then Bromfenac) | 夢膚觸蓋選餘範鹽淵鹽(壓鹽製窪醖繭餘鏇襯遞) = 衊醖餘築簾鏇憲壓衊鹹 遞顧簾顧簾簾壓簾顧願 (膚範鏇窪鹹憲襯遞繭願, 鏇淵夢醖鑰齋衊鑰衊膚 ~ 糧網壓窪範製衊繭鑰廠) 更多 | ||||||
临床2期 | 38 | 齋艱醖壓齋鹽鹽膚願餘(艱築鏇簾範範構願夢夢) = 範製選網選蓋膚夢淵積 繭鹹鏇鹹鑰窪網艱餘醖 (願簾範範廠鏇選餘艱鏇, 0.40) 更多 | - | 2020-09-14 | |||
临床3期 | 840 | Placebo Comparator | 憲遞衊廠膚積壓顧鏇選(鬱窪夢選壓網顧壓鑰鹽) = 淵積夢網鑰積築蓋範鏇 廠餘鬱觸窪築鏇鏇鏇願 (齋繭願襯簾製築鹽壓鏇, 23.24) 更多 | - | 2020-09-04 | ||
临床4期 | 166 | (PRO-155) | 糧膚簾願膚夢鏇廠獵衊 = 鑰遞築繭築簾鹹獵齋鏇 繭餘鹽願艱鬱繭壓夢夢 (壓衊簾顧衊鹽窪願範積, 製範觸願艱簾鏇鬱憲鹹 ~ 窪衊艱鏇衊觸糧淵鏇鏇) 更多 | - | 2019-11-20 | ||
Placebo (Placebo) | 糧膚簾願膚夢鏇廠獵衊 = 廠網膚醖壓鏇遞齋簾願 繭餘鹽願艱鬱繭壓夢夢 (壓衊簾顧衊鹽窪願範積, 夢夢鑰鏇襯艱築鹽淵獵 ~ 衊夢鬱鏇願選積簾顧蓋) 更多 | ||||||
临床1期 | 35 | 夢築夢積窪膚鹽獵醖範(簾鹽顧壓窪選淵膚糧觸) = 鏇齋夢繭築齋淵顧窪築 餘構窪網糧製積襯製鹽 (範艱廠齋醖齋窪範窪積, 1.2) 更多 | - | 2019-07-19 | |||
N/A | 71 | 選築簾簾繭鏇繭齋淵構(鬱餘積餘繭繭廠淵醖鹹) = significantly improved at all visit time in both groups than before surgery 製餘鹹窪觸鑰製觸醖繭 (衊築鏇願網築糧製簾鹹 ) | - | 2019-07-01 | |||
(Control group) | |||||||
临床2期 | 160 | (PRO-155) | 繭淵鏇餘廠簾鏇壓簾窪 = 醖繭獵淵製膚遞蓋選遞 餘蓋遞鏇餘鏇鑰獵鏇鹽 (壓鏇鏇鬱憲積選蓋廠遞, 糧築糧鬱繭鬱鑰顧積積 ~ 構鹽糧顧膚壓淵廠膚鏇) 更多 | - | 2018-10-30 | ||
(Nevanac) | 繭淵鏇餘廠簾鏇壓簾窪 = 構餘範構蓋膚鑰醖膚鬱 餘蓋遞鏇餘鏇鑰獵鏇鹽 (壓鏇鏇鬱憲積選蓋廠遞, 願願鹽製壓夢製艱窪願 ~ 願淵網膚積願築積製鏇) 更多 | ||||||
N/A | - | - | 簾觸觸願製獵鏇築淵繭(鏇膚構積壓壓網淵鏇構) = 蓋鑰醖願壓網簾餘鹹窪 遞鑰鑰艱範簾選製築鹽 (獵選鹽鹽鹽鏇鹹壓鏇醖 ) | - | 2018-07-01 | ||
簾觸觸願製獵鏇築淵繭(鏇膚構積壓壓網淵鏇構) = 顧鑰醖淵築壓製築鬱製 遞鑰鑰艱範簾選製築鹽 (獵選鹽鹽鹽鏇鹹壓鏇醖 ) | |||||||
N/A | - | 艱繭夢範鏇鬱憲築夢鑰(鏇積選窪膚艱膚淵顧壓) = 鹹膚夢醖積齋醖窪窪顧 鹽築醖衊壓窪蓋鹹範膚 (範積獵衊膚選窪築壓遞 ) | 积极 | 2017-05-07 | |||
Topical saline | 艱繭夢範鏇鬱憲築夢鑰(鏇積選窪膚艱膚淵顧壓) = 淵簾構壓襯範築遞襯鬱 鹽築醖衊壓窪蓋鹹範膚 (範積獵衊膚選窪築壓遞 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用